A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine as Adjuvant to Opioids in Terminally Ill Cancer Patients With Refractory Cancer Pain (CIVIK Trial).
Kownoh ParkJae-Joon KimSang-Bo OhSo Yeon OhYun Jeong HongSeo-Jun KimEun-Ju ParkNayeon ChoiSeon-Hi ShinSungeun KimHeejung KoPublished in: The American journal of hospice & palliative care (2024)
This study showed efficacy of gradually increasing CIVI of ketamine for terminally ill cancer patients with refractory cancer pain. CIVI of ketamine could be a useful tool in these patients considering the limited treatment options. (NCT03362073, Initial Release: November 15, 2017).
Keyphrases
- papillary thyroid
- pain management
- chronic pain
- squamous cell
- phase ii study
- end stage renal disease
- chronic kidney disease
- early stage
- lymph node metastasis
- ejection fraction
- low dose
- newly diagnosed
- neuropathic pain
- radiation therapy
- high dose
- open label
- prognostic factors
- postoperative pain
- patient reported
- rectal cancer